RedHawk (SNDD) 10-Q 15 May 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 01, 2018
Document And Entity Information
Entity Registrant Name	RedHawk Holdings Corp.
Entity Central Index Key	1,353,406
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		351,049,027
Trading Symbol	IDNG
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Current Assets:
Cash	$ 28,835	$ 53,939
Certificate of deposit	100,000
Receivables	193,961	548,992
Inventory, at cost	243,864	364,331
Assets held for sale	745,854	745,854
Prepaid expenses	38,747	44,626
Total Current Assets	1,351,261	1,757,742
Other Assets
Investment in real estate limited partnership	625,000	625,000
Intangible asset, net of amortization of $274,906 and $243,408, respectively	432,543	528,583
Total Other Assets	1,057,543	1,153,583
Total Assets	2,408,804	2,911,325
Current Liabilities:
Accounts payable and accrued liabilities	669,785	860,104
Liabilities on assets held for sale	244,580	251,252
Current portion of convertible notes payable, net of $33,484 in deferred loan costs	235,516
Line of credit	70,000
Insurance notes payable		7,225
Total Current Liabilities	1,219,881	1,118,581
Long-Term Debt:
Due to related party	28,666	35,000
Convertible notes payable, net of $40,713 and $42,914 in deferred loan costs and unamortized beneficial conversion of $64,492 and $80,842, respectively	615,878	462,384
Total Long-Term Debt	644,544	497,384
Total Liabilities	1,864,425	1,615,965
Commitments and Contingencies
Stockholders' Equity (Deficit):
Common Stock, par value of $0.001 per share, 1,000,000,000 authorized shares and 386,520,562 and 379,070,562 issued, respectively	386,520	379,071
Additional paid-in capital	1,268,174	1,254,889
Accumulated other comprehensive loss	(1,417)
Accumulated deficit	(3,772,910)	(3,243,543)
Total Stockholders' Equity (Deficit) Before Treasury Stock	909,731	1,308,962
Less, Treasury stock 35,471,535 and 18,021,535 shares, respectively, at cost	(365,352)	(76,102)
Total RedHawk Holdings Corp. Stockholders' Equity	544,379	1,232,860
Noncontrolling interest in foreign limited liability company		62,500
Total Stockholders' Equity	544,379	1,295,360
Total Liabilities and Stockholders' Equity	2,408,804	2,911,325
5% Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, 5,000 authorized shares and 2,723 issued and outstanding	1,639,397	1,579,425
5% Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, 5,000 authorized shares and 2,723 issued and outstanding	$ 1,389,967	$ 1,339,120

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Deferred loan costs, current	$ 33,484
Amortization of intangible assets	274,906	243,408
Deferred loan costs, noncurrent	40,713	42,914
Unamortized beneficial conversion	$ 64,492	$ 80,842
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	2,723	2,723
Preferred stock, shares outstanding	2,723	2,723
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	386,520,562	379,070,562
Treasury stock, shares	35,471,535	18,021,535
5% Series A Preferred Stock [Member]
Preferred stock, stated value per share	$ 1,113	$ 1,072
Preferred stock, shares designated	2,750	2,750
Preferred stock, shares issued	1,473	1,473
Preferred stock, shares outstanding	1,473	1,473
5% Series B Preferred Stock [Member]
Preferred stock, stated value per share	$ 1,112	$ 1,071
Preferred stock, shares designated	1,250	1,250
Preferred stock, shares issued	1,250	1,250
Preferred stock, shares outstanding	1,250	1,250

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues	$ 63,549	$ 338,931	$ 363,646	$ 1,556,548
Less, discounts	(580)	88,345	(106,547)	(732,156)
Revenues, net	62,969	427,276	257,099	824,392
Operating Expenses:
Costs of goods sold	7,972	70,031	112,984	195,136
Sales and marketing expenses	38,318	(6,217)	78,432	94,509
Professional fees	24,849	60,354	83,723	300,013
Management fees		10,928		60,000
Operating expenses	6,922	52,394	35,830	127,159
Depreciation and amortization	22,166	17,765	66,498	68,338
General and administrative	57,575	52,668	121,371	227,793
Total Operating Expenses	157,802	257,923	498,838	1,072,948
Net Income (Loss) from Operations	(94,833)	169,353	(241,739)	(248,556)
Other Income (Expense):
Amortization of discount on convertible debentures	(5,450)	(5,450)	(16,350)	(18,800)
Settlement loss			(62,425)
Gain (Loss) on the sale of assets		(839)		(4,834)
Dividend income		5		9,982
Interest expense	(58,439)	(11,469)	(98,045)	(54,881)
Total Other Income (Expense)	(63,889)	(17,753)	(176,820)	(68,533)
Net Income (Loss)	(158,722)	151,600	(418,559)	(317,089)
Other comprehensive income (loss):
Effect of foreign currency translation	5,714	41	(1,417)	(470)
Total Other comprehensive income	5,714	41	(1,417)	(470)
Comprehensive Income (Loss)	(153,008)	151,641	(419,976)	(317,559)
Less, income (loss) attributable to non-controlling interest		186,902		220,178
Comprehensive loss attributable to RedHawk Holdings Corp.	(153,008)	(35,261)	(419,976)	(537,737)
Preferred Stock Dividends	(37,399)	(31,125)	(110,819)	(93,375)
Comprehensive Loss Available for Common Stockholders	$ (190,407)	$ (66,386)	$ (530,795)	$ (631,112)
Net Loss Per Share
Basic
Diluted
Weighted Average Shares Outstanding
Basic	351,049,027	361,021,249	358,407,239	359,185,583
Diluted	351,049,027	361,021,249	358,407,239	359,185,583

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (418,559)	$ (317,089)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangibles	66,498	52,671
Net revenue considered a deemed distribution to noncontrolling interests		(313,177)
Amortization of discount on convertible debentures	16,350	18,800
Amortization of deferred loan costs	39,449	9,504
Depreciation		15,667
Loss on sale of marketable securities		10,318
Non-cash interest expense	22,365	21,844
Non-cash settlement loss	62,475
Changes in operating assets and liabilities:
Accounts receivable	(51,894)	270,618
Inventory	140,200	(243,542)
Prepaid expense and deposits	7,379	(43,339)
Accounts payable and accrued liabilities	(211,968)	127,499
Net Cash Used in Operating Activities	(327,705)	(390,226)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of certificate of deposit	100,000
Net proceeds from the sale of marketable securities		367,574
Investment in domestic limited liability company		(70,000)
Net Cash Provided by (Used in) Investing Activities	(100,000)	297,574
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from related party line of credit	22,916	161,613
Proceeds from issuance of convertible notes	402,328	210,000
Proceeds from sale of stock	20,735	24,584
Deferred loan costs	(70,732)	(10,826)
Net proceeds (payments) on bank line of credit	70,000	(1,000,495)
Net proceeds from insurance notes payable	(7,225)	(7,955)
Principal payments on convertible notes	(50,000)
Principal payments on long-term debt	(6,672)	(6,291)
Net Cash Provided by (Used in) Financing Activities	381,350	(629,370)
Effect of exchange rate on cash	21,250	11,283
Decrease in cash	(25,104)	(710,739)
Cash, Beginning of Period	53,939	727,631
Cash, End of Period	28,835	16,892
Non-Cash Investing and Financing Activities:
Beneficial conversion discount on convertible notes		42,000
Preferred stock dividends paid-in-kind	110,819	62,250
Convertible debt issued in exchange for treasury shares	29,250
Reduction in equity from share exchange to acquire 100% interest in Ecogen	311,590
Interest paid
Income tax paid

Consolidated Statements of Cas6

Consolidated Statements of Cash Flows (Parenthetical)	Mar. 31, 2018
Statement of Cash Flows [Abstract]
Interest acquitision , percentage	100.00%

Nature of Operations and Contin

Nature of Operations and Continuance of Business	9 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Continuance of Business	1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS RedHawk Holdings Corp. (formerly Independence Energy Corp.) was incorporated in the State of Nevada on November 30, 2005 under the name “Oliver Creek Resources Inc.” At inception, we were organized to acquire, explore and develop natural resource properties in the United States. Effective August 12, 2008, we changed our name from “Oliver Creek Resources Inc.” to “Independence Energy Corp.” and opened for trading on the Over-the Counter Bulletin Board under the symbol “IDNG.” Effective October 13, 2015, by vote of a majority of the Company’s stockholders, the Company’s name was changed from “Independence Energy Corp.” to “RedHawk Holdings Corp.” On March 31, 2014, the Company acquired the exclusive right to distribute certain medical devices and changed the focus of its operations to include medical device distribution. We have expanded our business focus to include other operations. Currently, we are a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials” and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. Centri Security Systems LLC, a wholly-owned subsidiary of the Company, holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner. Our real estate leasing revenues are generated from a commercial property under a long-term lease. Additionally, the Company’s real estate investment unit holds a limited liability company interest in a commercial restoration project in Hawaii. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will be able to continue as a going concern without further financing. The Company must continue to realize its assets to discharge its liabilities in the normal course of business. The Company has generated limited revenues to date and has never paid any dividends on its common stock and is unlikely to pay any common stock dividends or generate significant earnings in the immediate or foreseeable future. For the nine month period ended March 31, 2018, the Company had gross revenues of $363,646, net revenues of $257,099, a consolidated net loss of $418,559 and cash of $327,705 used in operating activities. For the year ended June 30, 2017, the Company had $1,670,488 in gross revenue, $929,859 in net revenue, a consolidated net loss of $407,681 and cash of $154,640 used in operating activities. As of March 31, 2018, the Company had cash and a certificate of deposit of $128,835, working capital of $131,380 and an accumulated deficit of $3,772,910. The continuation of the Company as a going concern is still dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, cash proceeds from the sale of assets and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited interim condensed financial statements of the Company as of March 31, 2018 and for the nine month and three month periods ended March 31, 2018 and 2017 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The year-end condensed balance sheet dated as of June 30, 2017 is audited and is presented here as a basis for comparison. Although the financial statements and related information included herein have been prepared without audit, and certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, the Company believes that the note disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K as of June 30, 2017. In the opinion of our management, the unaudited interim financial statements included herein reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results expected for the full year or any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost. Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Revenue Recognition We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and deducted from gross revenues. Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of March 31, 2018 and June 30, 2017. Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method. Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the twelve-month period ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, the net book value of those properties along with related mortgage notes are reflected as assets and liabilities held for sale in the balance sheets. At that time, we also ceased depreciating such assets. All such amounts are included in the land and hospitality segment. We expect the sale of those properties to occur in the fiscal year ending June 30, 2018 and have, accordingly, presented the held for sale assets and liabilities as current. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of March 31, 2018. We are also pursuing the sale of our real estate limited partnership investment, but we cannot conclude such a transaction would occur within one year and, therefore, have not reclassified related assets and liabilities as held for sale. Effective July 1, 2017, the Chemin Metairie Road property is leased under a one-year term at a rent of $1,500 per month. The lessee has an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. Although, there is no certainty that such sale will occur, we do believe the lessee will exercise that purchase option. The tenant that leases the Jefferson Street property has renewed that lease through December 31, 2022 at a rent of $3,500 per month. We continue to offer that property for sale and expect a sale to occur in our 2018 fiscal year. Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes, Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At March 31, 2018, including accrued but unpaid interest, there were 40,922,172 shares issuable upon conversion of the notes. There are $347,000 in convertible notes that are convertible at a variable conversion rate and not included in the issuable share amount in the preceding sentence. Also, at March 31, 2018, including accrued but unpaid dividends, there were potentially 109,293,125 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 138,996,711 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. Comprehensive Income (Loss) ASC 220, Comprehensive Income Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Reclassification Certain amounts in prior periods have been reclassified to conform to the current year presentation. Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. The adoption of this guidance in the current year did not have an impact on our financial position, results of operations, cash flows or disclosures. Leases In February 2016, the FASB issued ASU 2016-02, Leases

Other Assets

Other Assets	9 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Other Assets	3. OTHER ASSETS On December 31, 2015, RedHawk Land & Hospitality, LLC, a wholly-owned subsidiary of the Company, acquired from Beechwood Properties, LLC 280,000 Class A Units (approximately a 2.0% membership interest) of fully paid, non-assessable units of limited liability company interest in Tower Hotel Fund 2013, LLC, a real estate development limited liability company formed in the state of Hawaii for acquisition, restoration and development of the Naniloa Hilo Resort in Hilo, Hawaii. The $625,000 purchase price was paid by the issuance of 625 shares of the Company’s Series A Preferred Stock. The purchase price was determined by an independent third-party valuation. Beechwood Properties, LLC is a real estate limited liability company owned and controlled by G. Darcy Klug, a stockholder and Chief Financial Officer and Chairman of the board of directors of the Company. This investment in real estate limited partnership is recorded at cost and the Company is not aware of any indicator of impairment as of March 31, 2018. It is not practicable for the Company to estimate fair value of this investment. On March 23, 2016, one of our wholly-owned subsidiaries, RedHawk Pharma UK Ltd (which we refer to herein as “Pharma”), initially acquired a 25% equity interest in EcoGen Europe Ltd (which we refer to as “EcoGen”) from Scarlett Pharma Ltd (which we refer to herein as “Scarlett”). On September 12, 2017 we completed a share transfer agreement wherein we increased our ownership in EcoGen to 75%. On December 19, 2017 we completed another share transfer agreement wherein we increased our ownership in EcoGen to 100%. In connection with the December share transfer the non-controlling interest was eliminated. Under the terms of an agreement we reached with Scarlett and its affiliate related to these share exchanges, they surrendered ten (10) million shares of RedHawk common stock, and transferred to RedHawk approximately $300,000 of EcoGen preferred stock and other consideration. In exchange, RedHawk assumed approximately $370,000 of obligations due to EcoGen by Scarlett and its affiliates. The RedHawk Shares were originally issued to Scarlett in connection with the Company’s March 2016 investment of 25% into EcoGen. As of December 31, 2017, Pharma now owns approximately $635,000 of EcoGen’s preferred stock and 100% of EcoGen’s common stock. The exchange agreements also settled numerous outstanding disputes between the Company, Scarlett, Warwick and the noncontrolling owners of the Company. A non-cash settlement loss of $62,425 resulted and is included in our results for the nine months ended March 31, 2018. During the fiscal year ended June 30, 2017, we began to consolidate the accounts of EcoGen in our financial statements under the variable interest entity model. In the quarter ended September 30, 2017, we became the majority owner of EcoGen and as of December 31, 2017, we now own 100% of the common stock of EcoGen. As of March 31, 2018, we have approximately $417,008 ($382,008 net of accumulated amortization) in intangible assets related to licenses held by EcoGen. Such intangible assets are being amortized over an estimated useful life of 20 years, except for approximately $50,000 in licenses associated with certain pharmaceutical products which do not expire and are considered to have an indefinite life. This allocation to intangible assets is preliminary and may be adjusted as we complete the evaluation of EcoGen assets.

Loan and Insurance Note Payable

Loan and Insurance Note Payable	9 Months Ended
	Mar. 31, 2018
Loans Payable [Abstract]
Loan and Insurance Note Payable	4. LOAN AND INSURANCE NOTE PAYABLE We finance a portion of our insurance premiums. At March 31, 2018, there was no outstanding balance due on our premium finance agreements. The policies related to these premiums expire May 31, 2018.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	5. RELATED PARTY TRANSACTIONS Effective December 1, 2016, the Company entered into a $250,000 Commercial Note Line of Credit (which we refer to as the “Line of Credit”) with a stockholder and officer of the Company to evidence prior indebtedness and provide for future borrowings. The advances are used to fund our operations. The Line of Credit accrues interest at 5% per annum and matures on March 31, 2019. At maturity, or in connection with a pre-payment, subject to the conditions set forth in the Line of Credit, the stockholder has the right to convert the amount outstanding (or the amount of the prepayment) into the Company’s Series A Preferred Stock at the par value of $1,000 per share. During the year ended June 30, 2017, $250,000 of the amounts loaned under this line of credit were converted to preferred stock. At March 31, 2018, the principal balance totaled $28,666. The amount is included in noncurrent liabilities based on the expectation that either the Line of Credit maturity date will be extended, the outstanding amount will be refinanced through other long-term debt, or the amount outstanding will be converted to preferred stock as allowed for in the agreement. During the year ended June 30, 2017, EcoGen had sales to customers which are controlled by individuals which are shareholders of EcoGen and are the noncontrolling interests in our consolidated financial statements. These sales totaled $1,241,000 on a gross basis and had discounts of $968,000. A portion of these discounts were at levels that exceeded discounts offered to unaffiliated customers. During the quarter ended March 31, 2017, management of RedHawk and these noncontrolling shareholders of EcoGen reached an agreement whereby $370,000 of such discounts were to be considered an account receivable due to EcoGen by this affiliated customer. Subsequent to June 30, 2017, the Company assumed the obligations of these noncontrolling shareholders in connection with the share exchanges discussed in Note 3. Beginning in the quarter ended March 31, 2017, certain members of management agreed to forego management fees in consideration of the operating cash flow needs of the Company. There is not a set timeline to reinstitute such management fees. As of March 31, 2018, $60,000 in such fees remain unpaid and are recorded in accounts payable and accrued liabilities in the accompanying balance sheet.

Long-Term Debt, Debentures and

Long-Term Debt, Debentures and Line of Credit	9 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Long-Term Debt, Debentures and Line of Credit	6. LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT On November 12, 2015, we acquired certain commercial real estate from a related party that is an entity controlled by a stockholder and officer of the Company for $480,000 consisting of $75,000 of land costs and $405,000 of buildings and improvements (see Note 3). The purchase price was paid by through the assumption by the Company of $265,000 of long-term bank indebtedness (which we refer to as “Note”) plus the issuance of 215 shares of the Company’s newly designated Series A Preferred Stock. The purchase price also included the cost of specific security improvements requested by the lessee. The Note is dated November 13, 2015 and has a principal amount of $265,000. Monthly payments under the Note are $1,962 including interest accruing at a rate of 5.95% per annum. The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company. The Note is presented in the accompanying balance sheet as liabilities on assets held for sale (see “Property and Improvements” discussion in Note 1). We have authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Convertible Notes”). The Convertible Notes are secured by certain Company real estate holdings and real estate holdings of a stockholder. As of March 31, 2018, we have $990,083 in Convertible Notes outstanding, including the interest paid-in-kind on such notes. Prior to June 30, 2017, the Convertible Notes issued mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes. The Company may only issue the notice of its intent to redeem the Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Convertible Notes has the right to convert all or any portion of the Convertible Notes at the conversion price at any time prior to redemption. A portion of the convertible notes have a maturity date prior to March 31, 2019 and are, therefore, classified as a current liability. It is the Company’s expectation that we will re-finance these convertible notes to longer terms. If we do not re-finance these convertible notes to longer terms, however, the holders of the convertible notes have the option to convert these notes into equity or hold the convertible notes to maturity. At March 31, 2018, there were $990,803 ($851,394 net of deferred financing costs and beneficial conversion option) of Convertible Notes outstanding, including $58,833 of interest paid in kind. The Convertible Notes (plus accrued interest) are convertible into our common stock at a conversion rate of $0.015 per share or 40,922,172 shares. During the nine month periods ended March 31, 2018, we paid-in-kind $22,365 of interest on these convertible notes. During the nine months ended March 31, 2018, we also issued $400,000 of convertible notes to third parties with variable conversion rates. These convertible notes mature at various dates between November 2018 and May 2019. We received, net of financing costs incurred, $350,000 in cash from the issuance of these notes. These notes have interest accruing at rates ranging between 8% - 12%, and redemption and asset pledge terms similar to the other convertible notes. These notes issued to third parties have a variable conversion rate based on the price of the Company’s common stock. $119,500 of the convertible notes are convertible into our common stock beginning in the quarter ending June 30, 2018 at a variable conversion rate. We also refinanced a convertible note of $38,000 during the three months ended March 31, 2018 and we paid in full one convertible note in the amount of $50,000. Also, during the nine months ended March 31, 2018, we issued $29,250 of convertible notes to our majority stockholder in exchange for 7,450,000 shares of our common stock. The note matures in December 2020 and is convertible into 1,950,000 shares, or $0.015 per share. We had a $1,000,000 line of credit with a bank of which $1,000,495 was outstanding as of June 30, 2016. The line of credit was due upon demand and was secured by marketable securities, a corporate guarantee and the guarantee of a stockholder who is also an officer of the Company. During the twelve-month period ended June 30, 2017, the outstanding balance on the line of credit was paid in full. This line of credit is no longer available to the Company. In February 2018, we obtained a $100,000 line of credit from a bank. The line of credit matures in February 2021 and is collateralized by a $100,000 certificate of deposit at the bank. As of March 31, 2018, $70,000 was drawn under the line of credit and the interest rate was 6.5%.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. COMMITMENTS AND CONTINGENCIES On January 31, 2017, the Company and a stockholder filed a complaint (the “Complaint”) in the United States District Court for the Eastern District of Louisiana (RedHawk Holdings Corp. and Beechwood Properties, LLC Case No. 2:17-cv-819). The Complaint names Daniel J. Schreiber (“Schreiber”) and the Schreiber Living Trust – DTD 2/08/96 (the “Schreiber Trust”) as defendants. Schreiber is the former Chief Executive Officer and director of RedHawk. The Schreiber Trust, of which Schreiber is the Trustee, is a shareholder of the Company. The Complaint lodged claims on behalf of RedHawk for securities fraud, fraud, and Schreiber’s breach of fiduciary duties. On April 24, 2017, RedHawk and its shareholder filed an amended complaint (“Amended Complaint”) naming Schreiber as the only proper defendant in the suit, individually and as Trustee of the Schreiber Trust. On May 22, 2017, Schreiber filed a motion to dismiss, or in the alternative to transfer, the suit on the grounds of lack of personal jurisdiction and improper venue. After the parties filed an opposition and reply, on August 16, 2017 the court denied Schreiber’s motion to dismiss. On September 13, 2017, Schreiber filed an answer to the Amended Complaint, as well as counterclaims against RedHawk, Beechwood, and a director of RedHawk for actions allegedly taken in the course of his duty as a director. The counterclaims against RedHawk and its director are for alleged violation of UCC § 8-401, breach of fiduciary duty, negligence, and unfair trade practices. The legal remedies sought in these counterclaims were the subject of a lawsuit filed previously by Schreiber in the United States District Court for the Sothern District of California on April 24, 2017 (Case No. 3:17-cv-8824). At the time of the answer of the Louisiana lawsuit, the California action was still pending, and the answer asked that the counterclaim filed in Louisiana be stayed until the California case was adjudicated. On September 26, 2017, the court in the California action granted RedHawk’s motion to dismiss that suit. On October 10, 2017 a scheduling conference was held. The parties agreed to, among other matters, to exchange documents and conduct other discovery, and to schedule a bench trial starting June 11, 2018. RedHawk plans to vigorously contest the claims against it in this matter and to pursue the claims against Schreiber, individually and as Trustee of the Schreiber Trust.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2018
Stockholders' Equity (Deficit):
Stockholders' Equity	8. STOCKHOLDERS’ EQUITY Effective on October 13, 2015, we amended and restated our articles of incorporation as previously adopted by a majority vote of our stockholders. The amended and restated articles of incorporation, among other things, changed our name to RedHawk Holdings Corp., authorized 5,000 shares of Preferred Stock, and increased the number of authorized shares of common stock from 375,000,000 to 450,000,000. On December 26, 2017, by a vote of the majority of our stockholders, we increased the number of our authorized shares to 1,000,000,000. Preferred Stock Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After six months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends. During the three and nine month periods ended March 31, 2018, we paid-in-kind $37,399 and $110,819, respectively, of related preferred stock dividends. Warrants During November 2014, we completed a private equity sale of 14,905,918 shares of common stock generating proceeds of $49,900. As a component of this private equity sale, 7,452,959 warrants to acquire common stock of the Company were also issued with an exercise price of $0.005 per share. During the twelve-month period ended June 30, 2017, 3,726,480 warrants were exercised, and the remaining warrants expired.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES As of June 30, 2017, the Company had approximately $2,800,000 of U.S. net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2037. The related deferred income tax asset of these net operating losses was estimated to be approximately $1,000,000 as of June 30, 2017. The loss for the nine months ended March 31, 2018 is expected to increase the net operating loss carry forward by an amount similar to the book income of its U.S. operations. As of March 31, 2018, the Company had approximately $3,200,000 of U.S. net operating loss carry forwards. As a result of the enactment of the Tax Cuts and Jobs Act (The Act) in December 31, 2017, the estimated deferred income tax asset related to the carry forwards as of March 31, 2018 is $675,000 which is based on the reduced 21% corporate income tax rate. There is no net tax asset recorded as of March 31, 2018 or June 30, 2017 as a 100% valuation allowance has been established for the tax benefit generated. EcoGen also has a net operating loss as of June 30, 2017 and March 31, 2018 for which no deferred tax asset has been provided. The Company did not have any accumulated foreign earnings for which taxes were deferred and subject to the one-time transition tax under The Act. The Company accounts for interest and penalties relating to uncertain tax provisions in the current period statement of operations, as necessary. The Company’s tax years from inception are subject to examination. Due to our history of operating losses and the uncertainty surrounding the realization of the deferred tax assets in future years, our management has determined that it is more likely than not that the deferred tax assets will not be realized in future periods. Accordingly, the Company has recorded a valuation allowance against its net deferred tax assets.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Information	10. SEGMENT INFORMATION SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information,” MEDICAL Nine months ended LAND & DEVICE & OTHER March 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 48,185 $ 315,461 $ - $ - $ 363,646 Operating revenues, net $ 48,185 $ 208,914 $ - $ - $ 257,099 Operating income (loss) $ 16,226 $ (114,194 ) $ (1,757 ) $ (142,014 ) $ (241,739 ) Interest expense $ 11,171 $ 1 $ - $ 86,873 $ 98,045 Depreciation and amortization $ - $ 66,498 $ - $ - $ 66,498 Identifiable assets $ 1,373,224 $ 10,515 $ 60 $ 1,025,005 $ 2,408,804 MEDICAL Nine months ended LAND & DEVICE & OTHER March 31, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 29,250 $ 1,527,298 $ - $ - $ 1,556,548 Operating revenues, net $ 29,250 $ 795,142 $ - $ - $ 824,392 Operating income (loss) $ (5,079 ) $ 137,718 $ (26,292 ) $ (354,903 ) $ (248,556 ) Interest expense $ 11,665 $ 766 $ - $ 42,450 $ 54,881 Depreciation and amortization $ 15,667 $ 52,671 $ - $ - $ 68,338 Identifiable assets $ 1,373,352 $ 589,530 $ 74,465 $ 562,456 $ 2,599,803 MEDICAL Three months ended LAND & DEVICE & OTHER March 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 14,250 $ 49,299 $ - $ - $ 63,549 Operating revenues, net $ 14,250 $ 48,720 $ - $ - $ 62,969 Operating income (loss) $ 6,995 $ (59,367 ) $ (32 ) $ (42,429 ) $ (94,833 ) Interest expense $ 3,642 $ (3 ) $ - $ 54,800 $ 58,439 Depreciation and amortization $ - $ 22,166 $ - $ - $ 22,166 MEDICAL Three months ended LAND & DEVICE & OTHER March 31, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 9,750 $ 329,181 $ - $ - $ 338,931 Operating revenues, net $ 9,750 $ 417,526 $ - $ - $ 427,276 Operating income (loss) $ 8,178 $ 121,337 $ (22,446 ) $ 62,284 $ 169,353 Interest expense $ 11,664 $ 766 $ - $ (961 ) $ 11,469 Depreciation and amortization $ (30 ) $ 17,795 $ - $ - $ 17,765

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	11. SUBSEQUENT EVENTS The Company evaluates subsequent events through the time of our filing on the date we issue our financial statements, which was on May 14, 2018. The following are matters which occurred subsequent to March 31, 2018: ● On April 12, 2018, Judge Vernon S. Broderick, United States District Court, Southern District of New York, signed an ORDER dismissing American Medical Distributors, Inc.’s third-party claim filed against RedHawk Holdings Corp. (Case #1:16-cv-06016). ● On April 19, 2018, the Company provided NOTICE to its insurance provider that the self-insured retention deductible for legal defense costs under its directors & officers insurance policy has been satisfied. Accordingly, under the terms and conditions of its directors & officers insurance policy, the Company believes future litigation costs in the matter RedHawk Holdings Corp., et. al. versus Daniel J. Schreiber, et. al. (Case # 2:17-cv-00819 United States District Court, Eastern District of Louisiana) are the responsibility of its insurance provider.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim condensed financial statements of the Company as of March 31, 2018 and for the nine month and three month periods ended March 31, 2018 and 2017 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The year-end condensed balance sheet dated as of June 30, 2017 is audited and is presented here as a basis for comparison. Although the financial statements and related information included herein have been prepared without audit, and certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, the Company believes that the note disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K as of June 30, 2017. In the opinion of our management, the unaudited interim financial statements included herein reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows for the periods presented. The results of operations for interim periods are not necessarily indicative of the results expected for the full year or any future period.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost.
Use of Estimates	Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Revenue Recognition	Revenue Recognition We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture, and market, branded generic pharmaceuticals, and certain other generic pharmaceuticals known as “specials”. Our real estate leasing revenues are from certain commercial properties under lease. The financial service revenue is from brokerage services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and deducted from gross revenues.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of March 31, 2018 and June 30, 2017.
Inventory	Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, needle destruction devices and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method.
Property and Improvements	Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the twelve-month period ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, the net book value of those properties along with related mortgage notes are reflected as assets and liabilities held for sale in the balance sheets. At that time, we also ceased depreciating such assets. All such amounts are included in the land and hospitality segment. We expect the sale of those properties to occur in the fiscal year ending June 30, 2018 and have, accordingly, presented the held for sale assets and liabilities as current. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of March 31, 2018. We are also pursuing the sale of our real estate limited partnership investment, but we cannot conclude such a transaction would occur within one year and, therefore, have not reclassified related assets and liabilities as held for sale. Effective July 1, 2017, the Chemin Metairie Road property is leased under a one-year term at a rent of $1,500 per month. The lessee has an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. Although, there is no certainty that such sale will occur, we do believe the lessee will exercise that purchase option. The tenant that leases the Jefferson Street property has renewed that lease through December 31, 2022 at a rent of $3,500 per month. We continue to offer that property for sale and expect a sale to occur in our 2018 fiscal year.
Income Taxes	Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes,
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At March 31, 2018, including accrued but unpaid interest, there were 40,922,172 shares issuable upon conversion of the notes. There are $347,000 in convertible notes that are convertible at a variable conversion rate and not included in the issuable share amount in the preceding sentence. Also, at March 31, 2018, including accrued but unpaid dividends, there were potentially 109,293,125 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 138,996,711 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive.
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Financial Instruments	Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current year presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. The adoption of this guidance in the current year did not have an impact on our financial position, results of operations, cash flows or disclosures. Leases In February 2016, the FASB issued ASU 2016-02, Leases

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of Segment Activity	The following table reflects our segments as of March 31, 2018 and 2017 and for the nine and three month periods then ended. MEDICAL Nine months ended LAND & DEVICE & OTHER March 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 48,185 $ 315,461 $ - $ - $ 363,646 Operating revenues, net $ 48,185 $ 208,914 $ - $ - $ 257,099 Operating income (loss) $ 16,226 $ (114,194 ) $ (1,757 ) $ (142,014 ) $ (241,739 ) Interest expense $ 11,171 $ 1 $ - $ 86,873 $ 98,045 Depreciation and amortization $ - $ 66,498 $ - $ - $ 66,498 Identifiable assets $ 1,373,224 $ 10,515 $ 60 $ 1,025,005 $ 2,408,804 MEDICAL Nine months ended LAND & DEVICE & OTHER March 31, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 29,250 $ 1,527,298 $ - $ - $ 1,556,548 Operating revenues, net $ 29,250 $ 795,142 $ - $ - $ 824,392 Operating income (loss) $ (5,079 ) $ 137,718 $ (26,292 ) $ (354,903 ) $ (248,556 ) Interest expense $ 11,665 $ 766 $ - $ 42,450 $ 54,881 Depreciation and amortization $ 15,667 $ 52,671 $ - $ - $ 68,338 Identifiable assets $ 1,373,352 $ 589,530 $ 74,465 $ 562,456 $ 2,599,803 MEDICAL Three months ended LAND & DEVICE & OTHER March 31, 2018 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 14,250 $ 49,299 $ - $ - $ 63,549 Operating revenues, net $ 14,250 $ 48,720 $ - $ - $ 62,969 Operating income (loss) $ 6,995 $ (59,367 ) $ (32 ) $ (42,429 ) $ (94,833 ) Interest expense $ 3,642 $ (3 ) $ - $ 54,800 $ 58,439 Depreciation and amortization $ - $ 22,166 $ - $ - $ 22,166 MEDICAL Three months ended LAND & DEVICE & OTHER March 31, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 9,750 $ 329,181 $ - $ - $ 338,931 Operating revenues, net $ 9,750 $ 417,526 $ - $ - $ 427,276 Operating income (loss) $ 8,178 $ 121,337 $ (22,446 ) $ 62,284 $ 169,353 Interest expense $ 11,664 $ 766 $ - $ (961 ) $ 11,469 Depreciation and amortization $ (30 ) $ 17,795 $ - $ - $ 17,765

Nature of Operations and Cont20

Nature of Operations and Continuance of Business (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues	$ 63,549	$ 338,931	$ 363,646	$ 1,556,548	$ 1,670,488
Revenues, net	62,969	427,276	257,099	824,392	929,859
Consolidated net loss	158,722	(151,600)	418,559	317,089	407,681
Net cash used in operating activities			327,705	390,226	154,640
Cash	28,835	$ 16,892	28,835	$ 16,892	53,939	$ 727,631
Working capital deficit	131,380		131,380
Accumulated deficit	$ 3,772,910		$ 3,772,910		$ 3,243,543

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Percentage of ownership	100.00%
Equity method ownership percentage	100.00%
Allowance for doubtful accounts
Number of warrants exercised		3,726,480
Warrant outstanding
Incremental common shares issuable upon conversion of debt securities	40,922,172
Convertible notes	$ 347,000
Series A Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock	109,293,125
Series B Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock	138,996,711
Chemin Metairie Road [Member]
Property lease term	1 year
Lease rent	$ 1,500
Payments to acquire property on lease	300,000
Jefferson Street [Member]
Lease rent	$ 3,500
Renewed lease term	Dec. 31, 2022
Building [Member]
Useful life	20 years
Minimum [Member] | Building Improvements [Member]
Useful life	5 years
Maximum [Member]
Equity method ownership percentage	20.00%
Maximum [Member] | Building Improvements [Member]
Useful life	10 years
Subsidiaries [Member] | Minimum [Member]
Percentage of ownership	50.00%
Equity method ownership percentage	20.00%
Subsidiaries [Member] | Maximum [Member]
Equity method ownership percentage	50.00%

Other Assets (Details Narrative

Other Assets (Details Narrative) - USD ($)	Dec. 19, 2017	Mar. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 12, 2017	Jun. 30, 2017	Mar. 23, 2016
Percentage of ownership			100.00%		100.00%
Settlement loss					$ 62,425
Intangible assets related to licenses			432,543		432,543			$ 528,583
Accumulated amortization			$ 274,906		$ 274,906			$ 243,408
EcoGen's Preferred Stock [Member]
Percentage of ownership			100.00%		100.00%
Amount of owned by pharma					$ 635,000
Transfer Agreement [Member] | EcoGen Preferred Stock [Member]
Consideration transferred amount	$ 300,000
Other consideration in exchange approximately	$ 370,000
Beechwood Properties, LLC [Member]
Number of units acquired		280,000
Percentage of membership interest acquired		2.00%
Consideration transferred amount		$ 625,000
Number of shares issued upon acquisition		625
EcoGen Europe Limited ("EcoGen") [Member]
Percentage of ownership									25.00%
EcoGen Europe Limited ("EcoGen") [Member] | Transfer Agreement [Member]
Increased percentage of ownership	100.00%						75.00%
EcoGen Europe Limited ("EcoGen") [Member] | Transfer Agreement [Member] | March 2016 investment [Member]
Percentage of ownership	25.00%
Scarlett Pharma Ltd ("Scarlett") [Member] | Transfer Agreement [Member]
Additional number of shares surrendered	10,000,000
EcoGen [Member]
Intangible assets related to licenses			$ 417,008		417,008
Accumulated amortization			$ 382,008		$ 382,008
Intangible assets, useful life					20 years
Licenses associated with certain pharmaceutical products					$ 50,000

Loan and Insurance Note Payab23

Loan and Insurance Note Payable (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Loans Payable [Abstract]
Insurance notes payable		$ 7,225
Debt due date	May 31, 2018

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2018	Mar. 31, 2017	Mar. 31, 2018	Jun. 30, 2017
Line of credit interest rate			6.50%
Line of credit maturity date	Feb. 28, 2021
Due to related party			$ 28,666	$ 35,000
Accounts payable and accrued liabilities			60,000
EcoGen [Member]
Total cost of sales				1,241,000
Sales discount				968,000
Sales discount considered an accounts receivable		$ 370,000
Commercial Note Line of Credit [Member]
Due to related party			$ 28,666
Preferred Stock [Member]
Line of credit converted into preferred stock				$ 250,000
5% Series A Preferred Stock [Member]
Preferred stock, stated value per share			$ 1,113	$ 1,072
Line of Credit [Member]
Commercial note line of credit			$ 250,000
Line of credit interest rate			5.00%
Line of credit maturity date			Mar. 31, 2019
Line of Credit [Member] | 5% Series A Preferred Stock [Member]
Preferred stock, stated value per share			$ 1,000

Long-Term Debt, Debentures an25

Long-Term Debt, Debentures and Line of Credit (Details Narrative)	Nov. 13, 2015USD ($)	Nov. 12, 2015USD ($)shares	Feb. 28, 2018USD ($)	Mar. 31, 2018USD ($)$ / shares	Mar. 31, 2018USD ($)days$ / sharesshares	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Interest paid in kind					$ 22,365
Net of financing costs				$ 851,394	851,394
Refinanced convertible debt				38,000
Repayment of convertible debt				50,000
Line of credit outstanding			$ 100,000	70,000	$ 70,000		$ 1,000,495
Line of credit, maturity date			Feb. 28, 2021
Line of credit, collateral value			$ 100,000
Line of credit interest rate					6.50%
Convertible Notes [Member]
Convertible promissory note principal	$ 265,000			$ 1,000,000	$ 1,000,000
Debt instrument, monthly payment	$ 1,962
Convertible promissory notes interest rate	5.95%			5.00%	5.00%
Description of maturity	The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company.				The Convertible Notes mature on the fifth anniversary of the date of issuance
Interest paid in kind					$ 58,833
Common stock conversion price | $ / shares				$ 0.015	$ 0.015
Description of call feature					Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes.
Debt instrument, convertible threshold percentage of stock price trigger					300.00%
Debt instrument, convertible threshold trading days | days					5
Convertible debt conversion value					$ 990,083
Deferred financing costs and beneficial conversion
Number of converted shares | shares					40,922,172
Convertible Notes Outstanding [Member]
Interest paid in kind					$ 990,803
Convertible Notes One [Member]
Convertible debt conversion value					$ 119,500
Convertible Notes One [Member] | Minimum [Member]
Convertible promissory notes interest rate				8.00%	8.00%
Convertible Notes One [Member] | Maximum [Member]
Convertible promissory notes interest rate				12.00%	12.00%
Line of Credit Due Upon Demand [Member] | Bank [Member]
Line of credit maximum borrowing capacity							$ 1,000,000
Series A Preferred Stock [Member]
Number of shares issuance | shares		215
Land [Member]
Payment to acquired real estate from a related party		$ 75,000
Building and Improvements [Member]
Payment to acquired real estate from a related party		405,000
Stockholder and Officer [Member]
Payment to acquired real estate from a related party		480,000
Purchase price from acquisition		$ 265,000
Third Parties [Member] | Convertible Notes One [Member]
Description of maturity					November 2018 and May 2019
Net of financing costs				$ 350,000	$ 350,000
Convertible debt conversion value					$ 400,000
Majority Stockholder [Member]
Description of maturity					December 2,020
Convertible debt conversion value					$ 29,250
Number of converted shares | shares					7,450,000
Majority Stockholder [Member] | Convertible Notes [Member]
Common stock conversion price | $ / shares				$ 0.015	$ 0.015
Number of converted shares | shares					1,950,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Feb. 16, 2016	Nov. 12, 2015	Nov. 30, 2014	Mar. 31, 2018	Mar. 31, 2018	Dec. 26, 2017	Jun. 30, 2017	Oct. 13, 2015
Preferred stock, authorized				5,000	5,000		5,000	5,000
Common stock, authorized				1,000,000,000	1,000,000,000		1,000,000,000
Dividends, preferred stock, paid-in-kind				$ 37,399	$ 110,819
Number of outstanding warrants
Number of warrants exercised							3,726,480
Private Equity Sale [Member]
Number of shares on private equity sale			14,905,918
Proceeds on sale of private equity			$ 49,900
Private Equity Sale [Member] | Warrant [Member]
Number of outstanding warrants				7,452,959	7,452,959
Exercise price of warrants				$ 0.005	$ 0.005
Number of warrants exercised							3,726,480
Series A 5% Convertible Preferred Stock [Member]
Preferred stock, authorized		2,750
Preferred stock, stated value		$ 1,000
Preferred stock cumulative dividend rate		5.00%
Preferred stock voting rights		Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share		$ 0.015
Series B 5% Convertible Preferred Stock [Member]
Preferred stock, authorized	1,250
Preferred stock, stated value	$ 1,000
Preferred stock cumulative dividend rate	5.00%
Preferred stock voting rights	Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share	$ 0.01
Minimum [Member]
Common stock, authorized								375,000,000
Maximum [Member]
Common stock, authorized						1,000,000,000		450,000,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Net operating losses carryforwards	$ 3,200,000	$ 2,800,000
Income tax future year description		Net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2037.
Deferred tax assets operating loss carryforwards	$ 675,000	$ 1,000,000
Reduced percentage of federal tax rate	21.00%
Deferred tax assets
Percentage of deferred tax assets valuation allowance		100.00%

Segment Information - Schedule

Segment Information - Schedule of Segment Activity (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Operating revenues, net	$ 62,969	$ 427,276	$ 257,099	$ 824,392	$ 929,859
Operating income (loss)	(94,833)	169,353	(241,739)	(248,556)
Interest expense	58,439	11,469	98,045	54,881
Depreciation and amortization	22,166	17,765	66,498	68,338
Identifiable assets	2,408,804		2,408,804		$ 2,911,325
Operating Segment [Member]
Operating revenues, gross	63,549	338,931	363,646	1,556,548
Operating revenues, net	62,969	427,276	257,099	824,392
Operating income (loss)	(94,833)	169,353	(241,739)	(248,556)
Interest expense	58,439	11,469	98,045	54,881
Depreciation and amortization	22,166	17,765	66,498	68,338
Identifiable assets	2,408,804	2,599,803	2,408,804	2,599,803
Land & Hospitality [Member] | Operating Segment [Member]
Operating revenues, gross	14,250	9,750	48,185	29,250
Operating revenues, net	14,250	9,750	48,185	29,250
Operating income (loss)	6,995	8,178	16,226	(5,079)
Interest expense	3,642	11,664	11,171	11,665
Depreciation and amortization		(30)		15,667
Identifiable assets	1,373,224	1,373,352	1,373,224	1,373,352
Medical Device & Pharma [Member] | Operating Segment [Member]
Operating revenues, gross	49,299	329,181	315,461	1,527,298
Operating revenues, net	48,720	417,526	208,914	795,142
Operating income (loss)	(59,367)	121,337	(144,194)	137,718
Interest expense	(3)	766	1	766
Depreciation and amortization	22,166	17,795	66,498	52,671
Identifiable assets	10,515	589,530	10,515	589,530
Other Services [Member] | Operating Segment [Member]
Operating revenues, gross
Operating revenues, net
Operating income (loss)	(32)	(22,446)	(1,757)	(26,292)
Interest expense
Depreciation and amortization
Identifiable assets	60	74,465	60	74,465
Corporate [Member] | Operating Segment [Member]
Operating revenues, gross
Operating revenues, net
Operating income (loss)	(42,429)	62,284	(142,014)	(354,903)
Interest expense	54,800	(961)	86,873	42,450
Depreciation and amortization
Identifiable assets	$ 1,025,005	$ 562,456	$ 1,025,005	$ 562,456